AveXis (NASDAQ:AVXS)‘s stock had its “hold” rating reissued by stock analysts at Royal Bank of Canada in a research report issued on Tuesday, January 9th. They currently have a $92.00 price target on the stock. Royal Bank of Canada’s price objective would indicate a potential downside of 25.64% from the stock’s current price.
Other research analysts also recently issued research reports about the stock. Citigroup set a $132.00 target price on shares of AveXis and gave the stock a “buy” rating in a report on Friday, January 5th. Chardan Capital restated a “buy” rating and set a $135.00 price objective on shares of AveXis in a report on Friday, January 5th. UBS Group set a $122.00 price objective on shares of AveXis and gave the stock a “buy” rating in a report on Friday, January 5th. BMO Capital Markets reiterated an “outperform” rating and set a $123.00 target price on shares of AveXis in a research report on Saturday, September 30th. Finally, Morgan Stanley set a $120.00 target price on shares of AveXis and gave the company a “buy” rating in a research report on Friday, January 5th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $113.89.
AveXis (NASDAQ:AVXS) opened at $123.73 on Tuesday. AveXis has a 52 week low of $52.40 and a 52 week high of $128.00.
AveXis (NASDAQ:AVXS) last issued its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same quarter in the prior year, the business earned ($0.87) EPS. equities research analysts anticipate that AveXis will post -6.23 earnings per share for the current fiscal year.
In related news, VP James J. Litalien sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $106.52, for a total transaction of $532,600.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $109.75, for a total transaction of $1,646,250.00. Following the sale, the insider now owns 1,808,386 shares in the company, valued at $198,470,363.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,560 shares of company stock worth $4,152,752. 18.60% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of AVXS. Janus Henderson Group PLC acquired a new stake in AveXis during the 2nd quarter worth approximately $55,439,000. BlackRock Inc. boosted its position in AveXis by 34.7% during the 2nd quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock worth $189,069,000 after buying an additional 592,843 shares during the period. Alliancebernstein L.P. boosted its position in AveXis by 4,448.8% during the 2nd quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock worth $46,418,000 after buying an additional 552,546 shares during the period. FMR LLC boosted its position in AveXis by 13.1% during the 2nd quarter. FMR LLC now owns 4,705,433 shares of the company’s stock worth $386,598,000 after buying an additional 544,475 shares during the period. Finally, State Street Corp boosted its position in AveXis by 104.2% during the 2nd quarter. State Street Corp now owns 1,000,001 shares of the company’s stock worth $82,163,000 after buying an additional 510,189 shares during the period. Institutional investors and hedge funds own 82.77% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Royal Bank of Canada Reiterates Hold Rating for AveXis (AVXS)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/01/royal-bank-of-canada-reaffirms-hold-rating-for-avexis-avxs.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.